Johnson & Johnson Acquires Ollin Biosciences, Aims to Revolutionize Wet AMD Treatment with Bispecific Antibody OLN324
Johnson & Johnson’s $2.2B buy of Ollin Biosciences fuels a new bispecific eye drug, OLN324, poised to transform wet AMD and diabetic macular edema treatment with broader efficacy and longer dosing intervals.
4 minutes to read









